KromaTiD Announces Launch of New Product, dGH In-Site™

LONGMONT, Colo., June 9, 2020 /PRNewswire/ -- KromaTiD, Inc. announced today the launch of its new product dGH In-Site™, a single-cell, high resolution, genome-wide DNA insert trac...

Learn More

Boulder Biotech Company to be Acquired for $1.4B

Just a few weeks ago, the company filed for an IPO. Now, it's being acquired. Find out more in the article from Denver Business Journal.

Learn More

Brickell Biotech, Inc. Announces Pricing of $20.1 Million Underwritten Public Offering

BOULDER, Colo., June 17, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescri...

Learn More

Edgewise Therapeutics Appoints Kirsten L. Gruis, M.D., M.S. as Chief Medical Officer

Neuromuscular Expert Joins as Company Prepares Lead Muscular Dystrophy Product Candidate for Clinical Development Boulder, Colo., (June 17, 2020) – Edgewise Therapeutics, a biopharmaceu...

Learn More

ArcherDX Enters Collaboration with Bristol Myers Squibb to Apply Personalized Cancer Monitoring (PCM™) to Clinical Research

Aims to Inform use of Minimal Residual Disease (MRD) Monitoring in Clinical Trial Protocols and Future Therapy Optimization BOULDER, Colo., June 18, 2020 /PRNewswire/ – ArcherDX, Inc. today annou...

Learn More

Cetya Therapeutics Announces Issuance of New Patents Covering its HDAC Inhibitor CT-102

Drug candidate active against EGFR and KRAS mutant lung cancer cell lines Fort Collins, CO, June 11, 2020 – Cetya Therapeutics, Inc. today announced issuance of US Patent No. 10,676,504 and Australian...

Learn More

Flagship Biosciences Names Aymii Couzelis as Chief Information Officer

Westminster, Colorado (May 27, 2020) —Flagship Biosciences, providers of expert tissue data insights, today announced that Aymii Couzelis has been named to its executive team as Chief Information Offi...

Learn More

ARCA Biopharma Announces AB201 Development Program For Treatment of COVID-19 Associated Coagulopathy

Westminster, CO, May 28, 2020 – ARCA biopharma, Inc. (Nasdaq: ABIO) today announced a new development program to evaluate AB201 (rNAPc2), a potent, selective inhibitor of tissue factor (TF), as a pote...

Learn More

$7.3 Million Advanced Industries Awards Fuel 27 Colorado Start-ups

Colorado Office of Economic Development and International Trade (OEDIT)’s Advanced Industries Accelerator Grant Program realeased a list of 27 Colorado start-ups approved for funding. A total of...

Learn More

ArcherDX Receives Breakthrough Device Designation to Detect NTRK Gene Fusions

ArcherDX, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its next-generation sequencing (NGS) device under development as a compa...

Learn More